Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery

Journal of Pharmaceutical Sciences

Volumn 103, Issue 2, 2014, Pages 557-566

  Abu Lila, Amr S ^a,b   Uehara, Yumi ^a   Ishida, Tatsuhiro ^a   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Zagazig University   (Egypt)

Author keywords

Accelerated blood clearance (ABC) phenomenon; Anti PEG IgM; Clearance; Lipoplexes; Non viral gene delivery; PEGylation; Plasmid DNA (pDNA); Polyethylene glycol (PEG); Polyglycerol (PG)

Indexed keywords

CATIONIC LIPOSOME; GLYCEROL DERIVATIVE; IMMUNOGLOBULIN M; LIPOPLEX; LIPOSOME; MACROGOL; PLASMID DNA; POLYGLYCEROL; UNCLASSIFIED DRUG;

ACCELERATED BLOOD CLEARANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; IMMUNE RESPONSE; MALE; MOUSE; NEOPLASM; NONHUMAN; PLASMA CLEARANCE; RAT;

ACCELERATED BLOOD CLEARANCE (ABC) PHENOMENON; ANTI-PEG IGM; CLEARANCE; LIPOPLEXES; NON-VIRAL GENE DELIVERY; PEGYLATION; PLASMID DNA (PDNA); POLYETHYLENE GLYCOL (PEG); POLYGLYCEROL (PG);

ANIMALS; ANTIMETABOLITES; B-LYMPHOCYTES; BROMODEOXYURIDINE; CELL PROLIFERATION; CYTOKINES; DNA; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FLUORESCENT DYES; GENETIC THERAPY; GLYCEROL; IMMUNOGLOBULIN M; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PLASMIDS; POLYETHYLENE GLYCOLS; POLYMERS; RATS; RATS, WISTAR;

EID: 84895929589     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23823     Document Type: Article

References (49)

1. Ivics Z, Izsvak Z. 2006. Transposons for gene therapy! Curr Gene Ther 6(5):593-607.
2. Li SD, Huang L. 2006. Gene therapy progress and prospects: Nonviral gene therapy by systemic delivery. Gene Ther 13(18):1313-1319.
3. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. 2008. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 29(24-25):3477-3496.
4. Chen SH, Zhaori G. 2011. Potential clinical applications of siRNA technique: Benefits and limitations. Eur J Clin Invest 41(2):221-232.
5. Tseng YC, Mozumdar S, Huang L. 2009. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 61(9):721-731.
6. Nakamura K, Abu Lila AS, Matsunaga M, Doi Y, Ishida T, Kiwada H. 2011. A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol Ther 19(11):2040-2047.
7. Serikawa T, Suzuki N, Kikuchi H, Tanaka K, Kitagawa T. 2000. A new cationic liposome for efficient gene delivery with serum into cultured human cells: A quantitative analysis using two independent fluorescent probes. Biochim Biophys Acta 1467(2):419-430.
8. Gao X, Huang L. 1995. Cationic liposome-mediated gene transfer. Gene Ther 2(10):710-722.
9. Felgner PL, Ringold GM. 1989. Cationic liposome-mediated transfection. Nature 337(6205):387-388.
10. Takakura Y, Nishikawa M, Yamashita F, Hashida M. 2002. Influence of physicochemical properties on pharmacokinetics of non-viral vectors for gene delivery. J Drug Target 10(2):99-104.
11. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C. 1991. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88(24):11460-11464.
12. Torchilin VP, Omelyanenko VG, Papisov MI, Bogdanov AA Jr., Trubetskoy VS, Herron JN, Gentry CA. 1994. Poly(ethylene glycol) on the liposome surface: On the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta 1195(1):11-20.
13. Ishida T, Ichihara M, Wang X, Kiwada H. 2006. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Control Release 115(3):243-250.
14. Ishida T, Maeda R, Ichihara M, Irimura K, Kiwada H. 2003. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release 88(1):35-42.
15. Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, Corstens FH, Storm G. 2001. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 298(2):607-612.
16. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, Corstens FH, Boerman OC. 2000. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 292(3):1071-1079.
17. Wang X, Ishida T, Kiwada H. 2007. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 119(2):236-244.
18. Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, Kiwada H. 2006. Injection of PEGylated liposomes in rats elicits PEGspecific Ig M, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 112(1):15-25.
19. Tagami T, Nakamura K, Shimizu T, Ishida T, Kiwada H. 2009. Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. J Control Release 137(3):234-240.
20. Tagami T, Nakamura K, Shimizu T, Yamazaki N, Ishida T, Kiwada H. 2010. CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes. J Control Release 142(2):160-166.
21. Tagami T, Uehara Y, Moriyoshi N, Ishida T, Kiwada H. 2011. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J Control Release 151(2):149-154.
22. Ishida T, Kiwada H. 2008. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 354(1-2):56-62.
23. Abu Lila AS, Kiwada H, Ishida T. 2013. The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage. J Control Release 172(1):38-47.
24. Cui J, Li C, Wang C, Li Y, Zhang L, Yang H. 2008. Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase. J Pharm Pharmacol 60(12):1651-1657.
25. Saadati R, Dadashzadeh S, Abbasian Z, Soleimanjahi H. 2013. Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: Effects of polymer dose, PEG coating, and encapsulated anticancer drug. Pharm Res 30(4):985-995.
26. Abu Lila AS, Nawata K, Shimizu T, Ishida T, Kiwada H. 2013. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against longcirculating liposomes upon repeated administration. Int J Pharm 456 (1):235-242.
27. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. 2007. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release 122(3):349-355.
28. Ishida T, Iden DL, Allen TM. 1999. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett 460(1):129-133.
29. Bartlett GR. 1959. Colorimetric assay methods for free and phosphorylated glyceric acids. J Biol Chem 234(3):469-471.
30. Stover TC, Kim YS, Lowe TL, Kester M. 2008. Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials 29(3):359-369.
31. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. 1993. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res 53(16):3765-3770.
32. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y. 1994. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54(4):987-992.
33. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. 2005. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23(4):457-462.
34. Brown WC, Estes DM, Chantler SE, Kegerreis KA, Suarez CE. 1998. DNA and a CpG oligonucleotide derived from Babesia bovis are mitogenic for bovine B cells. Infect Immun 66(11):5423-5432.
35. Urbaneja MA, Fidelio GD, Lucy JA, Chapman D. 1987. The interaction of an anti-lipid antibody (TEPC 15) with a model biomembrane system (monolayer). Biochim Biophys Acta 898(2):253-256.
36. Swartz Jr. GM, Gentry MK, Amende LM, Blanchette-Mackie EJ, Alving CR. 1988. Antibodies to cholesterol. Proc Natl Acad Sci USA 85(6):1902-1906.
37. Biro A, Cervenak L, Balogh A, Lorincz A, Uray K, Horvath A, Romics L, Matko J, Fust G, Laszlo G. 2007. Novel anti-cholesterol monoclonal immunoglobulin G antibodies as probes and potential modulators of membrane raft-dependent immune functions. J Lipid Res 48(1):19-29.
38. Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ. 2005. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J Pharmacol Exp Ther 312(3):1020-1026.
39. Cheng TL, Chen BM, Chern JW, Wu MF, Roffler SR. 2000. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug Chem 11(2):258-266.
40. Cheng TL, Wu PY, Wu MF, Chern JW, Roffler SR. 1999. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug Chem 10(3):520-528.
41. Peng SL. 2005. Signaling in B cells via Toll-like receptors. Curr Opin Immunol 17(3):230-236.
42. Krieg AM. 2002. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760.
43. Glaum MC, Narula S, Song D, Zheng Y, Anderson AL, Pletcher CH, Levinson AI. 2009. Toll-like receptor 7-induced naive human B-cell differentiation and immunoglobulin production. J Allergy Clin Immunol 123(1):224-230, e4.
44. Hanten JA, Vasilakos JP, Riter CL, Neys L, Lipson KE, Alkan SS, Birmachu W. 2008. Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol 9:39.
45. Judge A, McClintock K, Phelps JR, Maclachlan I. 2006. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 13(2):328-337.
46. Ishida T, Harada M, Wang XY, Ichihara M, Irimura K, Kiwada H. 2005. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surfacedensity and chain length of the first-dose liposomes. J Control Release 105(3):305-317.
47. Koide H, Asai T, Hatanaka K, Urakami T, Ishii T, Kenjo E, Nishihara M, Yokoyama M, Ishida T, Kiwada H, Oku N. 2008. Particle sizedependent triggering of accelerated blood clearance phenomenon. Int J Pharm 362(1-2):197-200.
48. Taguchi K, Urata Y, Anraku M, Watanabe H, Kadowaki D, Sakai H, Horinouchi H, Kobayashi K, Tsuchida E, Maruyama T, Otagiri M. 2009. Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice. Drug Metab Dispos 37(11):2197-2203.
49. Li C, Zhao X, Wang Y, Yang H, Li H, Tian W, Yang J, Cui J. 2013. Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan. Int J Pharm 443(1-2):17-25.